AstraZeneca’s top medical executive Cristian Massacesi will replace Bristol Myers’ current chief medical officer, Samit ...

Bristol-Myers Squibb Co.’s chief medical officer is stepping down from his role after six years at the company, a surprise ...

Bristol Myers Squibb has raided AstraZeneca to find its next chief medical officer, persuading Cristian Massacesi, M.D., to ...

Bristol Myers Squibb's chief medical officer, Samit Hirawat, is leaving the drugmaker to pursue new professional opportunities.

Cristian Massacesi, M.D., Joins Bristol Myers Squibb as Executive Vice President, Chief Medical Officer and Head of Development ...

Bristol Myers Squibb (NYSE:BMY) has tapped Cristian Massacesi, as executive vice president, chief medical officer, and head of development, effective August 1, 2025. Massacesi most recently served as ...

Detailed price information for Bristol-Myers Squibb Company (BMY-N) from The Globe and Mail including charting and trades.

Bristol Myers Squibb has appointed Cristian Massacesi, M.D., as Executive Vice President, Chief Medical Officer, and Head of Development.

Bristol-Myers Squibb Co is confident it will receive U.S. approvals for all three experimental drugs tied to a potentially higher payout for Celgene shareholders under terms of its acquisition of ...

Speaking during the Fierce JPM Week virtual conference, Bristol's CMO, Samit Hirawat, said the company's deucravacitinib is a novel TYK2 inhibitor "with a very specific downstream effect of ...

Samit Hirawat So we have not actually publicly talked about this specific indications yet; so I will reserve that because we need to align with our partners before we start to convey that.

Samit Hirawat: EVP,Chief Med.Offr.,Drug Dev. 4,250: $47.58: $202,215.00: The DividendRank report noted that among the coverage universe, BMY shares displayed both attractive valuation metrics and ...